Pfizer v. Prinston Pharmaceutical: Xeljanz Tofacitinib Patent Action Dismissed in 7 Days
Pfizer filed a patent infringement suit against Prinston Pharmaceutical in Delaware over its Xeljanz (tofacitinib) 10 mg tablets, asserting reissue patent USRE041783E. The case was voluntarily dismissed without prejudice just 7 days after filing — before Prinston had served any answer — leaving the dispute legally unresolved and refiling options open.
Pfizer’s Xeljanz Reissue Patent Suit Against Prinston: A 7-Day Filing and Retreat
On September 26, 2025, Pfizer Inc. — along with affiliated entities C.P. Pharmaceuticals International C.V., PF PRISM C.V., PBG Puerto Rico LLC, and PF PRISM IMB B.V. — filed a patent infringement action in the Delaware District Court (Case No. 1:25-cv-01202) against Prinston Pharmaceutical Inc. The suit asserted reissue patent USRE041783E in connection with Pfizer’s branded Xeljanz 10 mg tofacitinib tablets, and targeted Prinston’s generic 10 mg tofacitinib tablets. The case was assigned to Judge Colm F. Connolly.
On October 3, 2025 — just 7 days after filing — Pfizer filed a notice of voluntary dismissal pursuant to Rule 41(a)(1)(A)(i) of the Federal Rules of Civil Procedure, dismissing all claims without prejudice. The public record confirms that Prinston had not yet served an answer or a motion for summary judgment at the time of dismissal, which is the precise procedural threshold that permits a plaintiff to dismiss unilaterally as of right under Rule 41(a)(1)(A)(i). No court order was required, and no costs ruling was entered.
A 7-day lifespan is exceptionally brief even by the standards of ANDA-adjacent pharmaceutical patent disputes, which often settle or resolve over months. The dismissal without prejudice preserves Pfizer’s right to refile, suggesting the withdrawal may reflect an out-of-court resolution, a strategic recalibration, or a procedural correction — the public record does not disclose which. Prinston’s apparent lack of counsel on record and the absence of any defendant filing further obscures the underlying commercial dynamic. Stakeholders monitoring Xeljanz generic entry should note that the patent dispute remains formally unresolved.
Filing to Voluntary dismissal in 7 days
7 days from filing to dismissal — among the shortest ANDA-style patent actions on record in Delaware
Voluntarily dismissed without prejudice: what the Rule 41 exit means for both parties
Rule 41(a)(1)(A)(i): plaintiff’s unilateral right to dismiss
Under Rule 41(a)(1)(A)(i), a plaintiff may dismiss an action without a court order at any point before the defendant serves an answer or a motion for summary judgment. Pfizer’s notice confirms Prinston had not yet done either. This is a purely procedural exit — no merits were adjudicated, no judicial findings were made, and no order of dismissal was entered. The case simply ceased to exist as a live proceeding at the moment the notice was filed.
No merits rulingPublic record is silent on whether a deal was reached
A dismissal without prejudice means Pfizer retains the right to refile the same patent claims against Prinston in future. This contrasts with a dismissal with prejudice, which would permanently bar refiling on the same claims. The public record does not disclose whether the dismissal reflects a private settlement, a licensing arrangement, a consent agreement on generic entry timing, or a purely tactical withdrawal. Practitioners should not infer either outcome from the dismissal notice alone.
Refiling rights preservedPfizer exits cleanly — but USRE041783E remains enforceable
Pfizer’s voluntary withdrawal does not diminish the legal validity or enforceability of USRE041783E. The reissue patent continues to subsist and Pfizer retains all rights to assert it against Prinston or other generic filers. The speed of the dismissal — before any substantive litigation costs accrued — suggests Pfizer may have achieved its objective (whether delay, a consent agreement, or otherwise) outside formal proceedings.
Patent intactPrinston faces continued uncertainty over generic market entry
Without a merits ruling or a consent judgment on record, Prinston cannot point to a judicial finding of non-infringement or invalidity of USRE041783E. If no private agreement governs their product launch, the threat of a refiled action remains live. Generic manufacturers in similar ANDA-adjacent contexts typically seek explicit patent clearance or licensing terms before committing to commercial launch. Prinston’s exposure to a future suit under the same patent should not be discounted.
No clearance on recordFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Pfizer, Inc. | Company | Global biopharmaceutical company — holder of USRE041783E covering tofacitinib (Xeljanz) 10 mg tabletsSearch in Eureka ↗ |
| Defendant | Prinston Pharmaceutical, Inc. | Company | Generic pharmaceutical manufacturer targeting Pfizer’s Xeljanz 10 mg tofacitinib formulationSearch in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Pfizer, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice is unambiguous in its procedural scope: all claims are dismissed without prejudice, and the filing confirms Prinston had not yet answered. Under Rule 41(a)(1)(A)(i), this is a self-executing notice — it requires no judicial action. What it does not do is resolve the underlying infringement question. USRE041783E’s validity and scope remain untested in this proceeding. The inclusion of multiple Pfizer affiliates as named plaintiffs suggests a carefully assembled enforcement entity, and their collective withdrawal without prejudice keeps every legal option open.
USRE041783E — Tofacitinib (Xeljanz) 10 mg Tablet Formulation, Reissue Patent
USRE041783E is a reissue patent derived from US application 12/577790, covering tofacitinib — a Janus kinase (JAK) inhibitor marketed by Pfizer as Xeljanz — specifically in its 10 mg oral tablet form. Reissue patents undergo re-examination at the USPTO and are granted to correct defects in the original patent; they carry the same legal force as original grants and may include broadened or clarified claims. Tofacitinib is indicated for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, representing a significant revenue franchise for Pfizer.
The reissue designation of USRE041783E means its claim scope may differ materially from the original patent, potentially capturing generic formulations that the original claims did not expressly cover. For generic manufacturers developing ANDA-pathway tofacitinib products, this patent represents a live enforcement risk. Pfizer’s decision to assert it within days of a generic competitor’s apparent market preparation, and then withdraw just as quickly, suggests active monitoring and a willingness to use litigation as a negotiating lever in the JAK inhibitor space.
Should you run an FTO against USRE041783E before launching a tofacitinib product?
Any company developing, manufacturing, or commercialising a generic or biosimilar tofacitinib 10 mg tablet product should treat USRE041783E as a primary FTO checkpoint. The reissue status means its claims may be broader or differently scoped than the original grant, and Pfizer has demonstrated active enforcement intent with this filing. The absence of a merits ruling in the Prinston case means there is no judicial precedent on claim scope or validity that a competitor could rely on for clearance.
PatSnap Eureka’s FTO Search Agent can map the full claim landscape of USRE041783E against your product specifications, identify related Pfizer continuation and reissue filings in the tofacitinib family, and flag any post-grant proceedings that may affect claim scope. For R&D and regulatory teams preparing an ANDA or NDA submission touching this compound, Eureka’s patent family analysis and litigation monitoring tools provide real-time visibility into enforcement activity before it reaches the courthouse.
Run a freedom-to-operate analysis on USRE041783E to assess your product’s exposure
Run FTO in Eureka →Similar JAK Inhibitor & Small-Molecule Pharma Patent Cases in Delaware
Cases involving reissue patent enforcement and voluntary dismissal in pharmaceutical litigation before Delaware District Court, with a focus on JAK inhibitor and small-molecule ANDA-adjacent disputes.
What this case signals for the small-molecule pharma IP landscape
Ultra-short pharmaceutical patent filings in Delaware are rarely accidental — the Pfizer-Prinston timeline warrants close monitoring.
Reissue patents carry the same enforcement weight as originals
USRE041783E is a reissue patent, meaning it was re-examined and reissued by the USPTO to correct errors or broaden/clarify claims. Reissue patents are fully enforceable and can cover territory not captured in the original grant. Generic manufacturers and their counsel should treat reissue patents as a primary litigation risk, not a secondary one.
7-day dismissals in pharma signal private resolution — not weakness
When a major pharmaceutical plaintiff dismisses within days of filing — before the defendant has even appeared — the most commercially plausible inference is that the filing itself triggered a negotiation that resolved quickly. This pattern is consistent with consent agreements, delayed entry deals, or licensing terms negotiated in the shadow of litigation. The patent’s enforceability is unaffected.
Pfizer v Prinston — key questions answered
The case was dismissed without prejudice under Rule 41(a)(1)(A)(i) after just 7 days, meaning no merits ruling was issued and USRE041783E remains enforceable. Pfizer retains the right to refile. Generic market entry by Prinston is not judicially cleared by this dismissal, and any commercial launch without a licensing or consent agreement could trigger a new action.
USRE041783E is a USPTO reissue patent based on US application 12/577790, covering Pfizer’s tofacitinib 10 mg tablet formulation marketed as Xeljanz. Reissue patents are re-examined grants that may carry broadened or clarified claims versus the original. Pfizer asserted this patent against Prinston’s generic 10 mg tofacitinib tablets, making it a direct FTO concern for any ANDA-pathway competitor in this compound.
Under Rule 41(a)(1)(A)(i), a plaintiff may dismiss all claims unilaterally — with no court order required — before the defendant serves an answer or a motion for summary judgment. A dismissal without prejudice means the plaintiff can refile the same claims in the future. No merits are decided, no costs are typically awarded, and the patent’s validity and enforceability are untouched by the procedural exit.
The public record does not disclose the reason. The most commercially plausible explanations include a private settlement or licensing agreement reached after filing, a consent agreement governing Prinston’s generic launch timing, or a strategic withdrawal pending further due diligence. The without-prejudice nature of the dismissal suggests Pfizer did not concede any rights and retains full enforcement options.
Yes. A voluntary dismissal without prejudice has no effect on the patent’s legal status. USRE041783E remains in force, and Pfizer and its affiliates retain all rights to assert it in future proceedings against Prinston or any other generic manufacturer. No court found the patent invalid, unenforceable, or not infringed in this action.
PatSnap Eureka searches patents and litigation data to answer instantly.